TSHA Stock Forecast: Taysha Gene Therapies, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Taysha Gene Therapies, Inc. is $12. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 56 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Taysha Gene Therapies, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (73): Analysts have, on balance, been raising their forecasts.
Volatility (34): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
TSHA stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on TSHA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 17 Sept 2026 | Wolfe Research | Initiates | Outperform | — |
| 21 July 2026 | Goldman Sachs | Maintains | Buy | $11 → $13 |
| 2 July 2026 | Citizens | Reiterates | Market Outperform | $11 |
| 30 June 2026 | Baird | Maintains | Outperform | $12 → $15 |
| 30 June 2026 | Needham | Maintains | Buy | $12 |
| 23 June 2026 | B of A Securities | Maintains | Buy | — |
| 23 June 2026 | BMO Capital | Maintains | Outperform | — |
| 23 June 2026 | Citizens | Maintains | Market Outperform | — |
| 22 June 2026 | Needham | Maintains | Buy | — |
| 6 Apr 2026 | Canaccord Genuity | Maintains | Buy | — |
| 19 Mar 2026 | Chardan Capital | Maintains | Buy | — |
| 19 Mar 2026 | Needham | Maintains | Buy | — |
| 3 Mar 2026 | Needham | Reiterates | Buy | — |
| 6 Jan 2026 | Chardan Capital | Maintains | Buy | — |
| 5 Jan 2026 | Wells Fargo | Maintains | Overweight | — |
| 5 Nov 2025 | Chardan Capital | Maintains | Buy | — |
| 5 Nov 2025 | Citizens | Maintains | Market Outperform | — |
| 21 Oct 2025 | Raymond James | Initiates | Strong Buy | — |
| 17 Oct 2025 | Chardan Capital | Maintains | Buy | — |
| 17 Oct 2025 | Needham | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for TSHA.
This page is one stock. Monday covers all of them.
TSHA appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
TSHA vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Taysha Gene Therapies, Inc. returned −6.8% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
TSHA analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 221.1×
- Price / book
- 3.4×
- EV / EBITDA
- —
Cheaper than 2% of US stocks
Cheaper than 27% of US stocks
- Revenue growth (YoY)
- −100.0%
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
Higher than 1% of US stocks
- Return on equity
- −54.2%
- Return on assets
- −27.3%
- Dividend yield
- —
Higher than 21% of US stocks
Higher than 16% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Taysha Gene Therapies, Inc. has a market value of $1.2B and an enterprise value of $844.6M.
Revenue in the twelve months to 30 June 2026: $5.5M. The latest quarter shrank 100.0% year on year.
Net income over the same four quarters: −$149.6M, a −2728.0% net margin.
Free cash flow in the twelve months to 30 June 2026: −$135.6M.
Taysha Gene Therapies, Inc. employs 99 people — $55K of revenue per employee.
Data provided by Twelve Data
TSHA and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at TSHA’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Taysha Gene Therapies, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about TSHA
What is the TSHA stock price forecast for 2026-2027?
The median 12-month analyst price target for Taysha Gene Therapies, Inc. is $12, with estimates ranging from $9 to $19. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is TSHA stock a buy right now?
Of the 13 analysts covering Taysha Gene Therapies, Inc., 13 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Taysha Gene Therapies, Inc. 56 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank TSHA?
As at 21 Nov 2026, Taysha Gene Therapies, Inc. ranks 56 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (73 of 100).
Will TSHA stock go up?
No one can know that. What the data says: the median 12-month target from 13 analysts is $12, and Ticker Nerd's factor model ranks Taysha Gene Therapies, Inc. 56 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the TSHA stock forecast for 2030?
No analyst covering Taysha Gene Therapies, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TSHA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $19 over the next 12 months.
How has TSHA stock performed over the past year?
Taysha Gene Therapies, Inc. returned -6.8% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Taysha Gene Therapies, Inc. do?
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company focused on developing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Taysha Gene Therapies works on treatments designed to address the genetic root causes of rare neurological disorders, with a pipeline that includes programs for Rett syndrome, giant axonal neuropathy, CLN1 disease, CLN7 disease, SLC13A5 deficiency, fragile X syndrome, angelman syndrome, and tauopathies.
About Taysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company focused on developing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Taysha Gene Therapies works on treatments designed to address the genetic root causes of rare neurological disorders, with a pipeline that includes programs for Rett syndrome, giant axonal neuropathy, CLN1 disease, CLN7 disease, SLC13A5 deficiency, fragile X syndrome, angelman syndrome, and tauopathies. The company’s current work centers on advancing its lead clinical programs and translating AAV gene therapy platforms into potential disease-modifying medicines for underserved patient populations. Based in Dallas, Texas, Taysha Gene Therapies operates within the broader biotechnology sector, where it contributes to the development of specialized therapies for rare central nervous system disorders.
CEO Mr. Sean P. Nolan · 99 employees · United States · https://www.tayshagtx.com